XML 16 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Product revenues $ 660 $ 969 $ 1,391 $ 1,560
Cost of product revenues 324 401 596 811
Amortization of intangible assets 306 306 613 612
Gross profit 30 262 182 137
Development revenues:        
Government contracts and other 899 531 1,816 1,549
Total development revenues 899 531 1,816 1,549
Operating expenses:        
Research and development 1,951 2,992 4,451 6,281
Sales and marketing 525 1,263 1,202 2,202
General and administrative 1,469 2,119 3,714 4,227
Total operating expenses 3,945 6,374 9,367 14,396
Operating loss (3,016) (5,581) (7,369) (12,710)
Other income (expense):        
Interest income 5 7 19 18
Interest expense (444) (538) (866) (1,129)
Other income (expense), net (204) 63 148 228
Total other expense (643) (468) (699) (883)
Net loss $ (3,659) $ (6,049) $ (8,068) $ (13,593)
Basic and diluted net loss per share $ (0.59) $ (1.94) $ (1.32) $ (5.04)
Basic and diluted weighted average shares used in calculating net loss per share 6,166,459 3,125,087 6,092,125 2,699,362
Comprehensive loss:        
Net loss $ (3,659) $ (6,049) $ (8,068) $ (13,593)
Other comprehensive loss – foreign currency translation adjustments 131 (15) (150) (75)
Comprehensive loss $ (3,528) $ (6,064) (8,218) (13,668)
Azaya Therapeutics, Inc. [Member]        
Operating expenses:        
In process research and development acquired from Azaya Therapeutics     $ 0 $ 1,686